A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of
Oleclumab (MEDI9447) with or without Durvalumab in Combination with
Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma
* For Eligibility information, please click on the "Look up trial at NIH" link above *
Other eligibility criteria may apply.
Other exclusion criteria may apply.